Evidence map›Paper›PMID 24304472›Full record

ArticleJournal of cellular and molecular medicine2014

α₁ adrenoceptor activation by norepinephrine inhibits LPS-induced cardiomyocyte TNF-α production via modulating ERK1/2 and NF-κB pathway.

Xiaohui Yu, Baoyin Jia, Faqiang Wang, Xiuxiu Lv, Xuemei Peng, Yiyang Wang, Hongmei Li, Yanping Wang, Daxiang Lu, Huadong Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Heliyon · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. αFrontiers in immunology · 2022
    Article
  8. Article
  9. Evidence for the Benefits of Melatonin in Cardiovascular Disease.Frontiers in cardiovascular medicine · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. αScientific reports · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xiaohui YuDepartment of Pathophysiology, Key Laboratory of State Administration of Traditional Chinese Medicine of the People's Republic of China, School of Medicine, Jinan University, Guangzhou, Guangdong, China.
Baoyin Jia
Faqiang Wang
Xiuxiu Lv
Xuemei Peng
Yiyang Wang
Hongmei Li
Yanping Wang
Daxiang Lu
Huadong Wang
Jinan University · CNState Administration of Traditional Chinese Medicine of the People's Republic of China · CNFirst Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiomyocyte tumour necrosis factor α (TNF-α) production contributes to myocardial depression during sepsis. This study was designed to observe the effect of norepinephrine (NE) on lipopolysaccharide (LPS)-induced cardiomyocyte TNF-α expression and to further investigate the underlying mechanisms in neonatal rat cardiomyocytes and endotoxaemic mice. In cultured neonatal rat cardiomyocytes, NE inhibited LPS-induced TNF-α production in a dose-dependent manner. α₁- adrenoceptor (AR) antagonist (prazosin), but neither β₁- nor β₂-AR antagonist, abrogated the inhibitory effect of NE on LPS-stimulated TNF-α production. Furthermore, phenylephrine (PE), an α₁-AR agonist, also suppressed LPS-induced TNF-α production. NE inhibited p38 phosphorylation and NF-κB activation, but enhanced extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation and c-Fos expression in LPS-treated cardiomyocytes, all of which were reversed by prazosin pre-treatment. To determine whether ERK1/2 regulates c-Fos expression, p38 phosphorylation, NF-κB activation and TNF-α production, cardiomyocytes were also treated with U0126, a selective ERK1/2 inhibitor. Treatment with U0126 reversed the effects of NE on c-Fos expression, p38 mitogen-activated protein kinase (MAPK) phosphorylation and TNF-α production, but not NF-κB activation in LPS-challenged cardiomyocytes. In addition, pre-treatment with SB202190, a p38 MAPK inhibitor, partly inhibited LPS-induced TNF-α production in cardiomyocytes. In endotoxaemic mice, PE promoted myocardial ERK1/2 phosphorylation and c-Fos expression, inhibited p38 phosphorylation and IκBα degradation, reduced myocardial TNF-α production and prevented LPS-provoked cardiac dysfunction. Altogether, these findings indicate that activation of α₁-AR by NE suppresses LPS-induced cardiomyocyte TNF-α expression and improves cardiac dysfunction during endotoxaemia via promoting myocardial ERK phosphorylation and suppressing NF-κB activation.

Indexed as

Adrenergic alpha-1 Receptor AgonistsAdrenergic alpha-1 Receptor AntagonistsAnimalsAnimals, NewbornButadienesEndotoxemiaEnzyme InhibitorsGene Expression RegulationImidazolesLipopolysaccharidesMiceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3MyocardiumMyocytes, CardiacNF-kappa B4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazoleAdrenergic alpha-1 Receptor AgonistsAdrenergic alpha-1 Receptor AntagonistsButadienesEnzyme InhibitorsImidazolesLipopolysaccharidesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NF-kappa BNitrilesNorepinephrinep38 Mitogen-Activated Protein KinasesPhenylephrinePrazosinProto-Oncogene Proteins c-fosPyridinesTumor Necrosis Factor-alphaU 0126cardiomyocytesLipopolysaccharideTumour necrosis factor-αα1-adrenoceptor

Identifiers

PMID24304472
PMCPMC3930413
OpenAlexW2064374502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.